Načítá se...
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
BACKGROUND: Frequently a biomarker capable of defining a patient population with enhanced response to an experimental agent is not fully validated with a known threshold at the start of a phase II trial. When such candidate predictive markers are evaluated and/or validated retrospectively, over-accr...
Uloženo v:
| Vydáno v: | Chin Clin Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4255950/ https://ncbi.nlm.nih.gov/pubmed/25485277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2304-3865.2013.12.04 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|